Aarti Pharmalabs Limited Asset Resilience Ratio
Aarti Pharmalabs Limited asset resilience ratio. Aarti Pharmalabs Limited (AARTIPHARM) has an Asset Resilience Ratio of 1.69% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Aarti Pharmalabs Limited (AARTIPHARM) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Aarti Pharmalabs Limited (2023–2025)
Asset resilience ratio of Aarti Pharmalabs Limited from 2023 to 2025. This chart shows how Aarti Pharmalabs Limited's Asset Resilience Ratio has changed over time. Read AARTIPHARM liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Aarti Pharmalabs Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Aarti Pharmalabs Limited (AARTIPHARM) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs491.23 Million | 1.69% |
| Total Liquid Assets | Rs491.23 Million | 1.69% |
Asset Resilience Insights
- Limited Liquidity: Aarti Pharmalabs Limited maintains only 1.69% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Aarti Pharmalabs Limited Industry Peers by Asset Resilience Ratio
Compare Aarti Pharmalabs Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329 |
Drug Manufacturers - Specialty & Generic | 5.92% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
Aarti Pharmalabs Limited Asset Resilience Ratio by Year (2023–2025)
Aarti Pharmalabs Limited asset resilience ratio by year from 2023 to 2025. The table below shows the annual Asset Resilience Ratio data for Aarti Pharmalabs Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 1.69% | Rs491.23 Million ≈ $5.31 Million |
Rs29.06 Billion ≈ $314.32 Million |
-1.04pp |
| 2024-03-31 | 2.73% | Rs703.98 Million ≈ $7.61 Million |
Rs25.82 Billion ≈ $279.24 Million |
+0.45pp |
| 2023-03-31 | 2.27% | Rs509.90 Million ≈ $5.51 Million |
Rs22.44 Billion ≈ $242.68 Million |
-- |
About Aarti Pharmalabs Limited
Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous sys… Read more